Introduction
The MAP kinase and PI3 kinase signaling pathways are among the best understood signal transduction pathways. The MAP kinase pathway is a major mitogenic signaling pathway activated by receptor protein tyrosine kinases (RPTKs). Activated RPTKs recruit adapter molecules such as Grb2, initiating a Ras/Raf kinase cascade leading to activation of MAP kinase (Schaeer and Webber, 1999) . MAP kinase is a serine/threonine protein kinase that phosphorylates and activates cytoplasmic substrates such as p90Rsk. It can also translocate to the nucleus where it phosphorylates and activates speci®c transcription factors. PI3K, on the other hand, is a lipid kinase that is recruited to the membrane by RPTKs upon ligand stimulation. Activated PI3K phosphorylates the D3 position of phosphatidylinositol lipids. These D3 phosphorylated phosphoinositides (D3 PPIs) can then recruit other signaling molecules to the membrane by binding to the pleckstrin homology (PH) domains of those molecules, thus leading to activation of signaling pathways downstream of PI3 kinase (Lemmon et al., 1996) . One of the important substrates identi®ed in the PI3K signaling pathway is protein kinase B (PKB)/Akt. Akt is a serine/threonine kinase that is translocated to the membrane via interaction of its PH domain with D3 PPIs (Bellacosa et al., 1998) . Once recruited to membrane it can be activated by PI3 kinase-dependent kinases (PDKs) (Downward, 1998) . Akt itself activates several signaling cascades involved in cell cycle regulation, glycolysis, glycogen synthesis, glucose transport and survival. It is also involved in protein synthesis via activation of p70S6 kinase.
The insulin (IR) and insulin-like growth factor-1 (IGFR) receptors activate both MAP and PI3 kinase pathways upon ligand binding. They are heterodimeric transmembrane proteins composed of two extracellular a-subunits and two cytoplasmic b-subunits. Ligand binding to these receptors causes transphosphorylation on cytoplasmic tyrosine residues and subsequent recruitment and activation of downstream signaling molecules. In addition to the activation of the MAP and PI3 kinase pathways, IR and IGFR also activate phospholipase C-g (PLC-g) and signal transducers and activators of transcription (STATs, particularly Stat3, Stat5a, and Stat5b) (Chen et al., 1997; Zong et al., 1998) .
Although IR is widely known for its role in glucose metabolism, accumulating evidence suggests that IR may also be involved in growth and oncogenesis. By fusing the 5' truncated b-subunit of IR to a retroviral gag sequence, we have previously demonstrated the oncogenic potential of IR (Wang et al., 1987) . IR is known to be overexpressed in a number of cancers including breast cancer , ovarian cancer (Amfo et al., 1995) , thyroid cancer (Frittitta et al., 1999) , and glioblastomas (Ligon et al., 1998) and has been suggested to be involved in their tumor development. In addition, IR has recently been shown to be activated by insulin-like growth factor II (IGF-II) to promote fetal development (Louvi et al., 1997) and breast cancer progression . The IGFs are powerful mitogens in breast cancer cells. They were once known to act mainly through the IGFR. IGF-II is secreted in most malignant breast cancers and several other types of tumors (Werner and LeRoith, 1996) and has been shown to bind to one particular isoform of IR. IR has two isoforms generated by alternative splicing of exon 11 : IR-A (Ex117) and IR-B (Ex11+) (Yamaguchi et al., 1991) . Isoform A is more abundantly expressed in breast cancer cells and IGF-II preferentially binds to this isoform with high anity. In contrast to insulin, the binding of IGF-II to IR-A induces mitogenicity instead of metabolism suggesting a new autocrine/paracrine mitogenic pathway of IR in cancer cells .
The role of IGFR in cancer biology has been more extensively studied. IGFR has been documented to have a high mitogenic and transforming potential. Overexpression of the native human IGFR (hIGFR) in NIH3T3 cells resulted in increased saturation density, anchorage-independent growth in soft agar, and tumor formation in nude mice in a ligand-dependent manner (Kaleko et al., 1990) . Expression of an N-terminally truncated hIGFR (gag-IGFR) via a retroviral vector in chicken embryo ®broblast (CEF) produced a ligandindependent transforming phenotype (increased saturation density and anchorage-independent growth) but could not induce tumors in chicken (Liu et al., 1992) . Further deletion of the 20 amino acids immediately upstream of the transmembrane domain of the original gag-IGFR produced a highly oncogenic variant called NM1 .
Similar to the implication of IR in human cancers, the IGF system is also upregulated in many cancers through receptor overexpression and/or growth factor secretion. The IGF-1 receptor is highly expressed in a number of tumors including breast cancer (Papa et al., 1993) , ovarian cancer (Beck et al., 1994) , colon cancer (Guo et al., 1992) , Wilms' tumor (Werner et al., 1993) , thyroid cancer (Yashiro et al., 1989) , and lung cancer (Rotsch et al., 1992) . IGF-I is secreted in cancers such as small cell lung cancer, schwannoma, and leiomyosarcoma, while IGF-II is expressed in cancers such as primary liver tumor, Wilms' tumor, and rhabdomyosarcoma. Several cancers secrete both growth factors (Werner and LeRoith, 1996) . The IGF system can also be activated without receptor or growth factor overexpression via constitutive activation of the endogenous IGFR by other oncoproteins such as p60 src (Peterson et al., 1996) . Using IGFR knock-out cell lines IGFR was shown to be crucial for transformation by simian virus (SV40) large tumor antigen (TAg) (Sell et al., 1993) and Ha-ras (Sell et al., 1994) , thus supporting its role in cancer development.
The MAP and PI3 kinase pathways are also activated by non-receptor protein tyrosine kinases. Of these Src represents the prototype and the most widely studied. The list of Src substrates and its downstream signaling molecules are long and diverse. They include a group of substrates described above that are also activated by IR and IGFR. The other Src substrates include those involved in cytoskeletal organization (cortactin, vinculin, tensin, talin, p190RhoGAP, AFAP100), cell ± cell adhesion (p120CAS, b-catenin, g-catenin), cell ± matrix adhesion (b1-integrin, FAK, paxillin, p130CAS), cell ± cell communication (connexin 43), and RNA processing (Sam68) (for review see Brown and Cooper, 1996) .
The role of c-Src in the genesis and progression of human cancer is supported by a number of genetic and biochemical studies. Although no mutations similar to that of v-Src have been found in human tumors, alterations such as increased gene copy number, increased protein level and/or speci®c enzyme activity have been described in a variety of cancers (Biscardi et al., 1999) . For example, the severity of breast cancer is highly correlated with increased c-Src activity (Ottenho-Kal et al., 1992) . In gastrointestinal cancers, c-Src has been shown to be activated and its inhibition by Herbimycin A (Garcia et al., 1991) , antisense expression vectors (Staley et al., 1997) , or Nfatty acyl glycinal compounds that abrogate c-Src myristoylation (Shoji et al., 1990) , was shown to slow the growth of colon cancer cell lines suggesting its role in colon cancer progression. c-Src protein and activity levels have also been shown to be upregulated in lung cancer, skin cancer, cervical cancer, neuroblastoma, and myeloproliferative disorders (Biscardi et al., 1999) . A number of these cancers have also been shown to overexpress RPTKs. Simultaneous overexpression of cSrc and certain RPTKs suggests that the receptor and non-receptor protein tyrosine kinases may interact and synergistically promote the progression of those cancers.
Although there is increasing data about the role of IR, IGFR, and Src in cancers, less is known about the precise role of their downstream signaling pathways in the development of cancer. Most of the signaling pathways have been studied in chicken, mouse, and rat ®broblasts, yet the relevance of these pathways may be dierent in epithelial cells, from which most of the cancers originate. Considering that more than 85% of human cancers are epithelial in origin, it is important to understand the role of PTK signaling pathways in transformation of epithelial cells. For this purpose, we studied gag-IR, gag-IGFR, and v-Src induced transformation of rat intestinal epithelial (RIE) cells and assessed the signi®cance of two major signaling pathways, the MAPK and PI3K pathways, in these cells. Our data demonstrate that the PI3 kinase pathway is activated by all three oncogenes in RIE cells and is required for their transformation by gag-IR and gag-IGFR, but less so by v-Src. MAP kinase is activated above the endogenous level in v-Src transformed RIE cells, but not in gag-IR and gag-IGFR transformed RIE cells. The MAPK is not required for gag-IR/IGFR induced transformation and appears to be partially required for the colony forming, but not the focus forming, ability of the vSrc transformed cells.
Results

Establishment of gag-IR-, gag-IGFR-, and v-Src-transformed RIE cells
To generate cell lines expressing gag-IR and gag-IGFR (Figure 1a ), pMX-T6 or pMX-NM1 (Liu et al., 1992; Poon et al., 1991) , plasmids were transfected into RIE cells via calcium phosphate co-precipitation. To establish ts-v-Src expressing cells pBABE-ts-v-Src (Lin and Gelman, 1997) was transfected into c-cre packaging cells and the rescued virus was used to infect parental RIE cells. The cells were then selected with their respective drug markers and mass cultures or individual clones were generated. RIE cells readily express gag-IR (T6), gag-IGFR (NM1), or ts-v-Src. The PTKs have constitutive kinase activity as shown by auto-phosphorylation or in vitro kinase activity (Figure 1b,c,d ). Overexpression of oncogenic PTKs in RIE cells resulted in a transformed phenotype as indicated by their ability to grow to a higher saturation density, form foci on monolayer, and form colonies in soft agar (see below). Morphologically, nontransformed RIE cells are cobblestone shaped (Figure 1e ) compared to the more refractile and elongated gag-IRand gag-IGFR-transformed cells (Figure 1f,g ). At the non-permissive temperature of 418C ts-v-Src-RIE cells morphologically resemble parental RIE cells and do not have focus and colony forming abilities. At 358C, ts-v-Src-RIE cells form foci and colonies eciently. They are highly refractile and assume a rounded morphology (Figure 1h ).
The MAP kinase signaling pathway is activated in v-Src, but not in gag-IR or gag-IGFR transformed cells
To examine the MAPK activation levels in these three oncogene transformed RIE cells, MAP kinase was immunoprecipitated from total lysate and subjected to an in vitro kinase assay using myelin basic protein (MBP) as the substrate. Alternatively, the immunoprecipitated MAP kinase was separated in a low crosslinking gel (75 acrylamide: 1 bis) to detect the MAP kinase mobility shift due to Thr/Tyr phosphorylation. No signi®cant increase in MAPK activation as detected by kinase assay or mobility shift was observed in mass culture and clones of T6 (gag-IR) or NM1 (gag-IGFR) expressing cells (Figure 3a) . However, MAPK was activated above the RIE basal level in the ts-v-Src-RIE mass culture at 358C (Figure 3b ). To examine the role of MAP kinase in gag-IR-, gag-IGFR-, and v-Src-induced transformation of RIE cells they were treated with the inhibitor, PD98059 (Figures 2 and 3c,d ). Our results indicated that MAP kinase was inhibited by PD98059 in a dosage dependent manner. At 10 mM, over 80% of the MAP kinase activity was abrogated in all three oncogene transformed RIE cells. The disparity in the basal MAP kinase levels of the RIE control cells observed in Figure  3a ,b re¯ects dierential autoradiography exposure times and variations among individual experiments.
The PI3 kinase signaling pathway is activated in gag-IR-, gag-IGFR-, and v-Src-transformed RIE cells and can be abrogated with wortmannin, LY294002, or rapamycin
We have previously shown that gag-IR and gag-IGFR are able to recruit and phosphorylate the adapter molecule IRS-1 (Chan et al., 1997; Jiang et al., 1996) . IRS-1 in turn activates PI3 kinase by binding to the regulatory p85 subunit of the PI3K complex (Giorgetti (Wang et al., 1987) . gag-IGFR contains 49 aa of the avian sarcoma virus UR2 gag Dp19 protein fused to the transmembrane and cytoplasmic domains of the insulin-like growth factor-1 receptor (IGFR) b-subunit (Liu et al., 1992) . The ts-v-Src lacks the C-terminal 19 amino acids of c-Src including the regulator Tyr-527 (Takeya et al., 1982) . Meyers et al., 1993) . Likewise, v-Src has been shown to associate with and activate PI3 kinase. To ascertain if gag-IR, gag-IGFR and v-Src transformed cells have increased PI3 kinase activity, the IRS-1 and v-Src associated activities were determined ( Figure 4a ). In contrast to MAP kinase, PI3 kinase was activated in all three oncogene transformed cells although there existed some variation in the degree of activation among the clones of gag-IR-and gag-IGFRtransformed cells (Figure 4a ). Since the PI3 kinase inhibitors LY294002 and wortmannin ( Figure 2 ) were to be used to evaluate the role of PI3 kinase signaling in the three oncogene mediated cell transformation, we assessed the eect of these pharmacological inhibitors on the total PI3 kinase activity in the transformed cells. Wortmannin and LY294002 were able to inhibit the total PI3 kinase activity in all three oncogene transformed cells substantially ( Figure 4b ). Further con®rmation of the PI3 kinase inhibition can be seen in the activation levels of Akt ( Figure 4c ). Akt is a downstream component of the PI3 kinase pathway and is activated upon phosphorylation of both Thr308 and Ser473. Using a phospho-Akt (Ser473) antibody to detect Akt activation, LY294002 was shown to decrease Akt Ser473 phosphorylation and thus activation in a dosage dependent manner. At 5 mM over 80 to 90% of the Akt phosphorylation was abrogated, at 10 mM no Akt phosphorylation at Ser473 was detectable in all three oncogene transformed cells indicating eective inhibition of the PI3 kinase activity by the drug (Figure 4c ). Akt can catalytically activate mTor/FRAP, which in turn activates p70S6 kinase. The antifungal and immunosuppressant agent, rapamycin, can block mTor/FRAP activity (Figure 2 ), therefore indirectly inhibiting the phosphorylation of p70S6 kinase at threonine 389 (Dennis et al., 1999) . At 1 ng/ml no Thr389 phosphorylated p70S6 kinase was detected in gag-IR-and gag-IGFR-transformed cells and only a residual amount of the activated p70S6 kinase was detected in the v-Src-transformed cells (Figure 4d ).
Effect of LY294002, PD98059 and rapamycin, on the growth of gag-IR/IGFR-RIE, and v-Src-RIE cells in monolayer
To determine biological consequences of inhibiting MAP kinase, PI3 kinase and p70S6 kinase the monolayer growth of transformed RIE cells were assessed. Cells were seeded at low density and treated with PD98059, LY294002 or rapamycin, respectively. Cells were grown and counted every other day for 6 days. PD98059 aected the growth of the parental RIE cells and the three oncogene transformed RIE cells similarly ( Figure 5 ). This indicates that there is no dierential requirement of the MAPK pathway Figure 4a ). These results, together, imply that the activation of PI3K in oncogene transformed RIE cells may have sensitized these cells to inhibition by LY294002 in monolayer growth. Inhibition of p70S6 kinase with rapamycin at one or ®ve ng/ml appeared to produce a similar eect on the control and transformed cells (Figure 7) . At the higher concentration (10 ng/ml), the inhibitory eect was apparently more pronounced in the transformed cells. The v-Src-RIE cells appeared to be slightly more sensitive to the rapamycin inhibition in comparison to the gag-IR-and gag-IGFR-transformed cells. Taken together, all three oncogene transformed cells display a similar pattern of sensitivity toward the drugs for their growth in monolayer. The PI3 kinase pathway appears to be more critically required than MAP kinase for the growth of these transformed cells in monolayer. The three oncogene transformed cells display an increased sensitivity toward the inhibitors of the PI3 kinase signaling pathway in comparison with the parental RIE cells.
The role of MAP kinase and PI3 kinase signaling pathways in colony and focus formation of the transformed RIE cells
To assess the role of MAP kinase and PI3 kinase signaling pathways in the anchorage-independent growth of gag-IR-, gag-IGFR-, and v-Src-transformed RIE cells, the various transformed cells were grown in soft agar with or without PD98059, LY294002 or rapamycin, respectively. Similarly, to inquire about the role of these pathways in the ability of the oncogene transformed cells to overcome contact inhibition, focus formation assays were performed in the absence or presence of the inhibitors. PD98059 at the concentration up to 25 mM had no signi®cant inhibitory eect on the focus formation of all three oncogene transformed cells (Figure 8a ). It did not inhibit the colony forming ability of gag-IR and gag-IGFR cells either, but had a mild inhibitory eect on that of the v-Src-RIE cells (Figure 9a ). LY294002 inhibited both colony and focus formation of gag-IR and gag-IGFR transformed RIE cells in a dosage dependent manner (Figures 8b and  9b) . Interestingly, v-Src transformed cells displayed a signi®cantly greater resistance toward inhibition of colony and especially focus forming ability by LY294002 (Figures 8b and 9b) . Quantitatively, treatment with 5 mM LY249002 caused colony formation of gag-IR-RIE and gag-IGFR-RIE cells to decrease to 50 and 58% and focus formation to 69.6 and 53.5% of the controls, respectively, while decreased colony formation of v-Src-RIE cells to 88.8% and did not aect v-Src-RIE focus formation at all (101% of control). At 5 mM of LY294002, where substantial inhibition of the activated Akt was already detected (Figure 4 ), no inhibition of focus formation and only 11% inhibition of colony formation of the v-Src transformed RIE cells was observed. Treatment with 10 mM LY294002 caused colony formation of gag-IR-RIE and gag-IGFR-RIE cells to decrease to 38.0 and 29.0% and focus formation to 43.8 and 22.5% of controls, respectively, while only decreased the colony and focus forming abilities of v-Src-RIE cells to 64 and 88.4% of controls, respectively. Rapamycin also had a signi®cant eect on colony and focus formation of the gag-IR/IGFR-RIE cells but had no appreciable eect on v-Src-RIE cells in either the colony or the focus forming ability (Figures 8c and 9c) .
To further corroborate the eects seen with LY294002 the transformed RIE cells were grown in soft agar in the presence of an independent PI3K inhibitor, wortmannin. The results indicate a similar pattern of inhibition as seen with LY294002: gag-IR- 4 parental RIE cells. The seeded cells were then incubated with either no inhibitor or with PD98059, LY294002, or rapamycin. Normal growth media with or without speci®c inhibitors were changed every 3 days. Cells were allowed to grow for 10 ± 14 days, then ®xed with 10% formalin, stained with Giemsa stain and the foci were counted RIE and gag-IGFR-RIE display a progressive decrease in colony forming ability with increasing concentration of wortmannin, while v-Src-RIE cells show no apparent inhibitory response to wortmannin ( Figure  10) . Additionally, the transformed RIE cells were transfected with a plasmid expressing a dominant negative form of PI3K, Dp85, which lacks the ability to associate with the catalytic p110 domain of PI3K. The gag-IR-RIE and gag-IGFR-RIE cells expressing the Dp85 were dramatically inhibited in their colony forming ability while v-Src-RIE cells were unaected (Figure 11 ). Thus, three approaches using two independent pharmacological inhibitors and a dominant negative form of PI3K support the conclusion that the PI3K pathway plays an essential role in the transforming ability of gag-IR-RIE and gag-IGFR-RIE cells, but less so in v-Src-RIE cells.
Discussion
The purpose of this study was to explore the role of the MAP and PI3 kinase signaling pathways in the transformation of RIE cells. To accomplish this we used oncogenic gag-IR, gag-IGFR and v-Src as our models. Oncogenic forms of IR and IGFR were used because of their constitutive kinase activity and increased transforming activity compared to the native receptors. Our studies of oncogenic gag-IR and gag-IGFR in ®broblast have shown that they activate the same signaling pathways as the activated native receptors (Liu et al., 1992 Poon et al., 1991; Baserga, 1995) . In this study, we show that the MAP kinase and PI3 kinase signaling pathways are dierentially required for transformation of the RIE cells by oncogenic gag-IR, gag-IGFR, and v-Src. The MAPK pathway is activated in v-Src-transformed, but not in gag-IR-and gag-IGFR-transformed RIE cells. It is unclear why MAPK is not activated above basal levels by gag-IR and gag-IGFR in RIE cells. While this is unexpected for IR and IGFR signaling, it may be a cell-speci®c phenomenon. Additionally, we tested if the basal MAPK activity in the gag-IR/IGFR-RIE cells and the activated MAPK activity in the v-Src-RIE cells were required for transformation of RIE cells by these oncogenes. Inhibiting the MAPK pathway aected parental RIE cells similarly as the three oncogene transformed cells in monolayer growth. This suggests that MAPK activity is partially required for the monolayer growth of the RIE cells whether or not they are transformed with these oncogenes. Inhibiting the MAPK pathway did not decrease the focus formation of all three oncogene transformed RIE cells (Figure 9a ), thus excluding its role in overcoming contact inhibition of the transformed RIE cells. Inhibiting MAPK substantially below the basal level did not appreciably aect the colony forming ability of gag-IR/IGFR-RIE cells either, therefore, also excluding its role in anchorage-independent growth of the RIE cells transformed by gag-IR or gag-IGFR. In contrast, the MAPK pathway appears to be partially needed for colony formation of the v-Src-RIE cells, and thus must play some role in their anchorageindependent growth. This ®nding corroborates with the observation that MAPK was activated only in v-Src, but not in gag-IR/IGFR cells. It also implies that gag-IR and gag-IGFR can activate signaling pathways abrogating the requirement of MAPK for anchorageindependent growth of the RIE cells whereas v-Src appears to rely somewhat on the MAPK pathway for this aspect of transformation.
Activation of IR and IGFR receptors has been shown to activate the MAP kinase pathway (Van der Greer et al., 1994) . Similarly, c-Src is also known to activate MAP kinase, especially when Src is transiently stimulated downstream of platelet-derived growth factor receptor (Conway et al., 1999; Ralston and Bishop, 1985) , G-coupled receptors (Luttrel et al., 1996) and integrins (Schlaepfer et al., 1998) . Interestingly, only v-Src was able to activate MAPK in RIE Figure 9 Eects of PD98059, LY294002, and rapamycin on the colony formation of gag-IR, gag-IGFR, and v-Src transformed RIE cells. A soft agar colony assay was performed as described in Materials and methods with or without the indicated pharmacological inhibitors. An overlay of DMEM containing 10% calf serum with or without the drug inhibitors was added every 3 days up to day 14. The colonies were stained with p-iodonitrotetrazonium (0.25 mg/ml) in normal growth media and counted cells while gag-IR and gag-IGFR were unable to do so. Activation of MAPK in v-Src-transformed RIE cells observed here raises an interesting contrast to the observation of previous reports in v-Src transformed ®broblasts (Aftab et al., 1997; Greulich et al., 1996; Stofega et al., 1997) . Those studies showed that MAPK was not activated in v-Src transformed NIH3T3, 3Y1, CEF and BalbC/3T3 cells and that MAPK activation above basal level was not required for transformation of these cells by v-Src as assayed by colony formation. This dierence may underscore the intrinsic dierential requirement of epithelial cells versus ®broblast for transformation. Our observation of up to 50% inhibition of the colony forming ability of v-Src-RIE Figure 10 Eect of wortmannin on the colony formation of gag-IR, gag-IGFR, and v-Src transformed RIE cells. A soft agar colony assay was performed as described in Materials and methods with or without wortmannin. An overlay of DMEM containing 10% calf serum with or without the drug inhibitors was added every 8 h up to day 14. The colonies were stained with piodonitrotetrazonium (0.25 mg/ml) in normal growth media and pictures were taken at 406magni®cation Figure 11 Eect of dominant negative PI3K, Dp85, on the colony formation of gag-IR, gag-IGFR, and v-Src transformed RIE cells. Four mg of empty vector or Dp85 expression vector were transfected into 1610 6 seeded transformed cells via calcium phosphate co-precipitation. Twenty-four hours post-transfection, soft agar colony assays were performed with 5610 4 transfected cells as described in Materials and methods. An overlay of DMEM containing 10% calf serum was added every 3 days up to day 14. The colonies were stained with p-iodonitrotetrazonium (0.25 mg/ml) in normal growth media and pictures were taken at 16magni®cation cells is in agreement with the study of Oldham et al. (1998) where they observed 40% inhibition of the vSrc-induced colony formation of RIE cells by PD98059.
Unlike the MAP kinase pathway, the PI3K pathway was found to be activated by all three oncogenes (Figure 4a ). Although wortmannin inhibits PI3K irreversibly, its half-life was relatively short (4 ± 8 h) and thus makes it more dicult for long-term biological experiments such as focus and colony formation assays which last 10 to 14 days; therefore, the more stable LY249002 was used in most of the experiments reported here. Rapamycin was used to inhibit mTor, leading to the inhibition of Thr389 phosphorylation required for activation of p70S6 kinase (Figure 4d ). The three oncogene transformed RIE cells appear to be more sensitive to the inhibition of PI3 kinase signaling than the parental cells for growth in monolayer (Figure 6 ). LY249002-induced apoptosis was ruled out as a possible cause of the decreased growth rate by TUNEL assay and by microscopic examination of the cell morphology after treatment of subcon¯uent cells with various concentrations of LY249002 (data not shown). Inhibition of p70S6K with rapamycin aected the monolayer growth of parental RIE and all three oncogene transformed cells with a similar pattern up to day 4 (Figure 7 ). Between day 0 and day 4, treatment with concentrations of rapamycin beyond 1 ng/ml did not have any more inhibitory eect on monolayer growth. By day 6, however, the RIE cells transformed by gag-IR and gag-IGFR showed a dose-dependent inhibition of monolayer growth that was less pronounced in parental RIE cells. These results indicate that the PI3 kinase pathway including the p70S6 kinase is important for the monolayer growth of parental and transformed RIE cells. Activation of signaling pathways by the three oncogenes appears to further sensitize the cells toward inhibitors of the pathways for their growth in monolayer. This concept is consistent with our observation from another study where we observed that breast cancer cells with ampli®ed MAP kinase or PI3 kinase signaling were more sensitive toward their respective inhibitors, as assayed by monolayer growth and colony formation, compared to the control cells or breast cancer cells without such ampli®cation (U Hermanto, CS Zong, and L-H Wang, unpublished) .
Our data show that the PI3K pathway is dierentially required for focus and colony formation of gag-IR/IGFR versus v-Src transformed RIE cells. Inhibiting the PI3K pathway with LY249002 dramatically aected focus and colony formation on gag-IR/IGFR-RIE cells, with a signi®cantly less eect on v-Src-RIE cells (Figures 8 and 9 ). This data was further con®rmed by studies using wortmannin and a dominant negative PI3K (Figures 10 and 11) . It is possible that v-Src may activate the PI3K pathway at a further downstream component or activate PI3K-independent pathways, hence allowing it to partially bypass the PI3K pathway for its transforming function. Any number of the diverse Src substrates, such as those involved in cytoskeletal reorganization, cell ± cell adhesion, cell ± matrix adhesion, or gene regulation such as Stat3 could potentially substitute for the PI3 kinase signaling function and contribute to the focus and colony forming ability of the v-Src-RIE cells. Stat3 has been shown to be required for transformation of ®broblasts by v-Src, Ros and gag-IGFR (Bromberg et al., 1998; Turkson et al., 1998; Zong et al., 1998) . v-Src also apparently targets molecules involved in the regulation of cell ± cell interaction, cell ± matrix interaction and cytoskeletal organization that may contribute to the rounded morphology and transforming properties of the v-Src-RIE cells.
p70S6 kinase regulates the multiple phosphorylation of 40S ribosomal protein S6, distinct from the p21Ras-Raf-MAPK-mediated phosphorylation of p90Rsk. p70S6K itself is regulated by Akt and by mTor/FRAP, which is inhibited by rapamycin ( Figure  2 ). The exact molecular mechanism for this regulation is not fully understood. Inhibition of p70S6K with rapamycin has been shown to inhibit cells in progressing through G1 phase of the cell cycle in Swiss 3T3 cells (Chung et al., 1992) . In our study, rapamycin partially inhibited the monolayer growth of the parental RIE and all three oncogene transformed cells (Figure 7 ). Rapamycin also inhibited the focus and colony formation of gag-IR-RIE and gag-IGFR-RIE but not the v-Src-RIE cells (Figures 8c and 9c ). This result is consistent with the relative resistance of v-Src-RIE cells to the inhibition of PI3 kinase for focus and colony formation. The results suggest that a basal level of p70S6K partially contributes to the monolayer growth of RIE cells and that transformation of RIE cells by these oncogenes further sensitized the RIE cells to the inhibitory eect of rapamycin. In addition, the p70S6K activity is required for gag-IR/ IGFR-, but not v-Src-, induced colony and focus formation.
Overall, our results show that activation of MAP kinase is not required for focus formation of all three oncogene transformed RIE cells, although MAP kinase is activated in the v-Src-transformed cells and is partially required for their colony forming ability. The PI3K-Akt-p70S6K pathway plays an important role for the monolayer growth, colony formation, and focus formation of the gag-IR and gag-IGFR transformed RIE cells, but is not as critical for transformation of RIE cells by v-Src. Penuel and Martin (1999) reported that transformation of CEF by v-Src is mediated by both MAP kinase and PI3 kinase signaling. Inhibition of either pathway resulted in only partial inhibition of focus and colony forming abilities of the v-Src transformed CEF, while inhibition of both substantially blocked the transformation. Taken together, it appears that the requirement of speci®c signaling pathways for transformation varies according to the type of cells and nature of the oncogenes. It would be interesting to identify the signaling pathway(s) activated in the v-Src-RIE cells that attenuates the requirement of the PI3 kinase signaling for transformation by oncogenic IR and IGFR.
Materials and methods
Cell culture
Rat intestinal epithelial (RIE) cells and RIE-transformed cells were maintained in Dulbecco's modi®ed Eagle's medium (DMEM) with 5% calf serum (CS).
Antibodies and reagents
Anti-IR, -IGFR, and -IRS-1 antibodies (Abs) were previously described (Chan et al., 1997; Jiang et al., 1996; Liu et al., 1992) . Anti-Src Ab (clone GD11) was purchased from Upstate Biotechnology Inc. Anti-Shc, anti-Erk-2 (C-14), anti-Akt, and anti-p70S6 kinase Abs were from Santa Cruz Biotechnology. Goat anti-rabbit IgG and goat anti-mouse IgG conjugated to horse-radish peroxidase (HRP), and RC20, a recombinant anti-p-Tyr conjugated to either alkaline phosphatase (AP) or HRP, were purchased from Transduction Laboratories. Goat anti-rabbit IgG-AP and goat anti-mouse IgG-AP were purchased from Roche. Antiphospho-Akt and anti-phospho-p70S6 kinase Abs were purchased from New England Biolabs. Phosphatidylinositol (PI) was purchased from Avanti Polar Lipids Inc. Wortmannin was purchased from Alexis biochemicals. LY294002 [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one], PD98059, and rapamycin were from Calbiochem. Mammalian expression vectors pMX-T6 and pMX-NM1 containing a Moloney LTR promoter and a neomyin resistance cassette were constructed in our laboratory pBabe-ts-v-src was obtained from Dr Irwin Gelman (Mount Sinai School of Medicine). Dominant Negative Dp85 was obtained from Dr Julian Downward.
Establishment of transformed RIE lines
Oncogenic gag-IR (T6) and oncogenic gag-IGFR (NM1) cell lines were established by transfection via calcium phosphate co-precipitation. 3610 5 cells per 60-mm dish were transfected with the pMX-T6 or pMX-NM1 ( Figure  1a) , selected 24 h post-transfection with G418 and individual clones and mass cultures were established. The plasmid encoding the temperature sensitive (ts) v-Src (Lin and Gelman, 1997) was transfected into c-cre packaging cells. The resulting ts-v-Src containing viruses were collected and then used to infect parental RIE cells. Cells were selected 24 h post-infection with the puromycin and individual clones and mass cultures were similarly established.
Protein analysis
Cellular proteins were extracted with either radio-immunoprecipitation assay (RIPA) buer (50 mM Tris [pH 7.5], 150 mM NaCl, 5 mM EDTA [pH 8.0], 1% deoxycholate, 1% Triton X-100, 1% Trasylo1, 1 mM Na 3 VO 4 , 1 mM phenylmethylsulfonyl¯uoride [PMSF]) or Nonidet P40 (NP40) buer (20 mM Tris [pH 7.5], 150 mM NaCl, 5 mM EDTA [pH 8.0], 1% Nonidet P40, 1% Trasylo1, 1 mM Na 3 VO 4 , 1 mM PMSF). Protein concentrations were determined and equivalent amounts of total cell lysate were resolved by SDS-polyacrylamide gel electrophoresis (SDS ± PAGE) and electrotransferred to nitrocellulose membranes for Western blotting. Alternatively, equivalent amounts of total cell lysate were used for immunoprecipitation and subsequent in vitro kinase assays.
In vitro Src kinase assay
Four hundred mg of total cell lysate was immunoprecipitated (IP) with Anti-Src (GD11) Ab in NP40 buer, washed twice with NP40 buer, and twice with freshly made kinase assay buer (50 mM Tris pH 8.0, 10 mM MnCl). The IP complex was then resuspended in 50 ml of kinase assay buer containing 10 mCi of g-32 P-ATP and incubated at room temperature for 20 min. The IP complex was spun down and washed twice with RIPA buer. The pellet was resuspended in 26SDS ± PAGE sample buer and boiled for 5 min. The proteins were then resolved by SDS ± PAGE and the gel dried and subjected to autoradiography.
MAP kinase assay
Four hundred mg of total cell lysate was immunoprecipitated (IP) with Anti-Erk-2 (C-14) Ab in NP40 buer, washed twice with NP40 buer and twice with the MAP kinase buer (10 mM HEPES [N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid] [pH 7.5], 10 mM magnesium acetate). The IP complex was then resuspended in 20 ml myelin basic protein (MBP) (2 mg/ml) and 20 ml of 36hot mix (150 mM ATP, 30 mM magnesium acetate, 30 mM HEPES) containing 5 mCi of g-32 P-ATP. The reaction mixture was incubated at 308C for 30 min with gentle mixing every 5 min. The reaction was stopped with addition of 66SDS ± PAGE sample buer and boiled for 5 min. The supernatant was collected and separated on a 15% SDS ± PAGE gel. The top half of the gel was transferred to a nitrocellulose ®lter and blotted for Erk protein expression as a control. The lower half of the gel was ®xed, stained with Coomassie blue, dried, and autoradiographed for [g- 
PI3 kinase assay
The PI3 kinase assay was performed as described previously (Fukui et al., 1989) with minor modi®cations as follows. Cells were lysed with NP40 buer on ice for 5 min and equal amounts of total cell lysate was immunoprecipitated with anti-IRS-1 Ab. The IP complex was washed three times with NP40 buer and a single wash by each of the following; PBS (phosphate buered saline), LT (0.5 M LiCl, 20 mM, TrisHCl [pH 7.5]), H 2 O, TEN (20 mM Tris-HCl [pH 7.5], 1 mM EDTA, 100 mM NaCl), and TGN (20 mM Tris-HCl [pH 7.5], 1 mM EGTA, 100 mM NaCl). The IP complex was then resuspended in a mixture containing 25 ml TGN buer and 0.5 ml phosphatidylinositol (PI) (20 mg/ml in DMSO) and incubated at room temperature for 10 min, with gentle agitation of the mixture several times, to form PI micelles. Ten mCi of g-32 P-ATP and MgCl 2 (®nal conc. 20 mM) were then added to the PI micelles and further incubated for 10 min at room temperature. The reaction mix was stopped with the addition of 150 ml stop solution (chloroform: methanol: 11.6N HCl=100 : 200 : 2). One hundred ml of chloroform was then added and the mixture was vortexed and centrifuged to separate the phases. The lower, organic phase was collected and washed three times with a wash solution (methanol:1 N HCl=1 : 1). The lipid samples in chloroform were dried, resuspended with 10 ml chloroform and spotted onto a Silica Gel 60 TLC plate (Merck). The lipid samples were separated by thin-layer chromatography with a solvent mix of chloroform:methanol:30% ammonium hydroxide: H 2 O (43 : 38 : 5 : 7) for 4 ± 5 h, air dried and exposed to Kodak XAR-5 ®lm with a Dupont intensifying screen at 7708C.
Growth rate assay
Cells were grown in medium containing 5% calf serum in the presence or absence of dierent concentrations of drug inhibitors. Cell numbers were counted every other day up to 6 days with Day 0 de®ned as the day when drug treatment started.
Focus formation assay
Five hundred T6-, NM1-, or v-Src-transformed RIE cells were seeded with 5610 5 parental RIE cells in duplicate 60 mm dishes. The following day one set of cultures were treated with 5% CS DMEM containing inhibitors while the other was replenished with normal growth media. Medium with or without drugs was changed every 3 days. Cells were ®xed 7 ± 10 days later with 10% formalin for 20 min at room temperature, then stained with 9.9 mg/ml Giemsa in 67 mM PO 4 buer (1 M Na 2 HPO 4 : 1 M NaH 2 PO 4 [2 : 1]).
Colony formation assay
5610
4 T6-, NM1-, or v-Src-transformed RIE cells were resuspended in 4 ml DMEM containing 0.41% Bacto agar supplemented with 10% CS, 10% tryptose phosphate broth (TPB), in the presence or absence of speci®c inhibitors (5, 10, or 25 mM PD98059; 5 or 10 mM LY294002; 1, 5, or 10 ng/ml rapamycin; 50, 100 or 250 nM wortmannin). The cell suspension was then overlaid onto a hard agar base composed of DMEM containing 0.72% Bacto agar supplemented with 10% CS, 10% TPB in 6 mm dishes. 10% CS DMEM with or without the speci®c inhibitor, was added to plates every 3 days as a feeder layer. For wortmannin, which has a much shorter half-life than LY294002, feeder layer was changed every 8 h. To analyse the eect of a dominant negative PI3K, Dp85, on the colony forming ability of the transformed cells, an empty plasmid or Dp85 expressing vector was transfected into the transformed cells via calcium phosphate co-precipitation. Twenty-four hours post-transfection, 5610 4 cells were subjected to colony formation assay as described above. The colonies were stained on day 10 to 14 with DMEM containing p-iodonitrotetrazonium (0.25 mg/ml) for 2 days in 378C before counting.
